IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Belshaw et al.

Serial No: 09/466,568

Filed: December 17, 1999

For: Regulated Gene Therapy Using Specific Response Elements

Attorney Docket No. APBI-P16-316

Art Unit: 1636

Examiner: Loeb, B. #25

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Commissioner for Patents, United States Patent and Trademark Office, Washington, D.C. 20231.

6/19/02
Date of Signature and of Mail Deposit

Anna P. Lucey

Commissioner for Patents
United State Patent and Trademark Office
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT IN COMPLIANCE WITH 37 CFR §§ 1.97(b) and 1.98(d)

Submitted herewith on Form PTO-1449 is a list of publications that applicants and their agents/attorneys have identified during the preparation of this application. In accordance with CFR § 1.98 (d), applicants respectfully submit that ***no copy*** of any patent, publication, or other information listed on the enclosed Form PTO 1449 is needed because the citations were made in prior application **U.S.S.N. 08/605,578**, filed February 22, 1996 which is relied upon for an earlier filing date under 35 U.S.C. 120.

Please charge our Deposit Account No. 18-1945 in the amount of $180.00 covering the fee set forth in 37 CFR 1.17(p).

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached Form 1449.

This submission does not represent that a search has been made or that no better art exists. Nor does it constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Respectfully submitted,
Ropes & Gray

By: _____
Matthew P. Vincent.
Reg. No. 36,709

Dated:

Customer No. 28120
Ropes & Gray
Patent Group
One International Place
Boston, MA 02110-2624

Form PTO-1449 **INFORMATION DISCLOSURE CITATION IN AN APPLICATION** *(Use several sheets if necessary)*	Docket Number (Optional) APBI-P16-316	Application Number 09/466,568
	Applicant Belshaw et al.	
	Filing Date December 17, 1999	Group Art Unit 1636

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,171,671	12/15/92	Evans et al.			
				COPY OF PAPERS ORIGINALLY FILED			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation YES	Translation NO
	AB	EP 594847	5/4/94	Europe				
	AC	WO 93/25533	12/23/93	PCT				
	AD	WO 93/23550	11/25/93	PCT				
	AE	WO 92/01052	1/23/92	PCT				

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages Etc.)*

	AF	Alberg et al. Structure-Based Design of a Cyclophilin-Calcineurin Bridging Ligand. *Science* 262, 248-250 (1993).
	AG	Albers et al. FKBP, Thought to be Identical to PKCI-2, Does Not Inhibit Protein Kinase C. *BioMed. Chem. Lett.* 1, 205-210 (1991).
	AH	Albers et al. An FKBP-Rapamycin Sensitive, Cyclin-Dependent Kinase Activity That Correlates with the FKBP Rapamycin-Induced G1 Arrest Point in MG-63 Cells. *Annals of N. Y. Acad. Sci.* 696, 54-62 (1993).
	AI	Albers et al. The Relationship of FKBP to PKCI-1. *Nature* 351, 527 (1991).
	AJ	Albers et al. Substrate Specificity for the Human Rotamase FKBP: A View of FK506 and Rapamycin as Leucine (twisted amide)-Proline Mimics. *J. Org. Chem.* 55, 4984 (1990).
	AK	Andrus et al. Structure-Based Design of an Acyclic Ligand That Bridges FKBP12 and Calcineurin. *J. Am. Chem. Soc.* 115, 10420-10421 (1993).
	AL	Ben-Levy et al. A oncogenic point mutation confers High Affinity Ligand Binding to the neu Receptor. *J. Biol. Chem.* 267, 17304-17313 (1992).
	AM	Bergsma et al. The Cyclophilin Multigene Family of Peptidyl-Prolyl Isomerases. *J. Biol. Chem.* 26, 23204 (1991).
	AN	Bernard et al. High-affinity Interleukin-2 Binding by an Oncogenic Hybrid Interleukin-2 Epidermal Growth Factor Receptor Molecule. *PNAS* 84, 2125-2129 (1987).
	AO	Bierer et al. The Effect of the Immunosuppressant FK506 on Alternate Pathways of T Cell Activation. *Eur. J. Immunol.* 21, 439-445 (1991).

Part of Papers No. 25

Form PTO-1449 **INFORMATION DISCLOSURE CITATION IN AN APPLICATION** *(Use several sheets if necessary)*	Docket Number (Optional) APBI-P16-316	Application Number 09/466,568
	Applicant Belshaw et al.	
	Filing Date December 17, 1999	Group Art Unit 1636

	AP	Bierer et al. Mechanisms of Immunosuppression by FK506: Preservation of T Cell Transmembrane Signal Transduction. *Transplantation* 49, 1168 (1990).
	AQ	Bierer et al. Probing Immunosuppressant Action with a Nonnatural Immunosuppressive Ligand. *Science* 250, 556 (1990).
	AR	Bierer et al. Two Distinct Signal Transmission Pathways in T Lymphocytes are Inhibited by Complexes Formed Between an Immunophilin and Either FK506 or Rapamycin. *PNAS* 87, 9231 (1990).
	AS	Bonnerot et al. Role of associated γ-chain in Tyrosine Kinase Activation via Murine FcRIII. *EMBO J.* 11, 2747-2757 (1992).
	AT	Bram et al. Identification of the Immunophilins Capable of Mediating Inhibition of Signal Transduction by Cyclosporin A and FK506: Roles of Calcineurin Binding and Cellular Location. *Mol. Cell. Biol.* 13, 4760-4769 (1993).
	AU	Byrn et al. Biological Properties of a CD4 Immunoadhesin. *Nature* 344, 667-670 (1990).
	AV	Cantley et al. Oncogenes and signal transduction. *Cell* 64, 281-302 (1991).
	AW	Chan et al. The ζ Chain is associated with a Tyrosine Kinase and upon T-Cell Antigen Receptor Stimulation Associates with ZAP-70, a 70-kDa Tyrosine Phosphoprotein. *PNAS* 88, 9166-9170 (1991).
	AX	Chung et al. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. *Cell* 69, 1227 (1992).
	AY	Clark et al. The B Cell Antigen Receptor Complex: Association of Ig-α and Ig-β with Distinct Cytoplasmic Effectors. *Science* 258, 123-126 (1992).
	AZ	Clipstone et al. Calcineurin: Molecular analysis of its interaction with drug-immunophilin complexes and its role in the regulation of NF-AT. *J. Cell. Biochem. Suppl.* 0 (18B) 274, Abstract #I410 (1994).
	BA	Crabtree, G. R. IL-2 receptor in the pathogenesis of human lymphoma. Abstract of NIH Grant R01CA39612 (1987).
	BB	Crabtree, G. R. Pathways of T lymphocyte activation. Abstract of NIH Grant R01CA39612 (1991).
	BC	Crabtree, G. R. Pathways of T lymphocyte activation. Abstract of NIH Grant R01CA39612 (1988).
	BD	DiLella et al. Chromosomal Band Assignments of the Genes Encoding Human FKBP12 and FKBP13. *Biochem. Biophys. Res. Commun.* 189, 819-823 (1992).
	BE	Donald et al. C10 N-Acyl Modified FK-506: A Possible Hybrid Analogue of the Transition State of Petidyl-Prolyl Cis-Trans Isomerization. *Tetrahedron Letters* 31, 1375-1378 (1991).
	BF	Durand. Characterization of Antigen Receptor Response Elements within the Interleukin-2 Enhancer. *Mol. Cell. Biol.* 8, 1715 (1988).

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	Docket Number (Optional) APBI-P16-316	Application Number 09/466,568
	Applicant Belshaw et al.	
	Filing Date December 17, 1999	Group Art Unit 1636

	BG	Eberle & Juninger. Synthesis of the Main Metabolite (OL-17) of Cyclosporin A. *J. Org. Chem.* 57, 2689-2691 (1992).
	BH	Edalji et al. High-Level Expression of Recombinant Human FK-Binding Protein from a Fusion Precursor. *J. Prot. Chem.* 11, 213 (1992).
	BI	Eiseman et al. Signal Transduction by the Cytoplasmic Domains of FcεRI-y and TCR0J-y in Rat Basophilic Leukemia Cells. *J. Biol. Chem.* 267, 21027-21032 (1992).
	BJ	Emmel et al. Cyclosporin A Specifically Inhibits Function of Nuclear Proteins Involved in T-Cell Activation. *Science* (1989).
	BK	Engel et al. High-Efficiency Expression and Solubization of Functional T-Cell antigen Receptor Heterodimers. *Science* 256, 1318-1321 (1992).
	BL	Evans et al. Mechanistic Study of the Rhodium(I)- and Iridium(I)- Catalyzed Hydroboration Reactions: Scope and Synthetic Applications. *J. Am. Chem. Soc.* 114, 6671-6679 (1992).
	BM	Fields, S. & Song, O. A Novel Genetic System to Detect Protein-Protein Interactions. *Nature* 340, 245-246 (1989).
	BN	Fischer et al. Mip protein of Legionella pneumophila exhibits peptidyl-prolyl-cis/trans isomerase (Pplase) activity. *Mol. Microbiol.* 6, 1375 (1992).
	BO	Fisher et al. On the Remarkable Propensity for Carbon-Carbon Bond Cleavage Reactions in the C8-C10 Region of FK-506. *J. Org. Chem.* 56, 2900-2907 (1991).
	BP	Flanagan et al. Intracellular signal transmission: a novel role for the prolyl isomerases. *J. Cell. Biochem. Suppl.* 0 (16 Part A) 61, Abstract #B005 (1992).
	BQ	Flanagan et al. Nuclear Association of a T-Cell Transcription Factor Blocked by a Tyrosine Factor Blocked by FK-506 and Cyclosporin A. *Nature* 352, 803-807 (1991).
	BR	Flanagan et al. Nuclear association of a transcription factor essential for T cell activation by cyclosporin A and FK506. *J. Cell. Biochem. Suppl.* 0 (16 Part B), 237, Abstract #H514 (1992).
	BS	Francavilla et al. Inhibition of Liver, Kidney, and Intestine Regeneration by Rapamycin. *Transplantation* 53, 496-498 (1992).
	BT	Fretz et al. Rapamycin and FK506 Binding Proteins (Immunophilins). *J. Am. Chem. Soc.* 113, 1409 (1991).
	BU	Friedman & Weissman. Two Cytoplasmic Candidates for Immunophilin Action are Revealed by Affinity for a New Cyclophilin: One in the Presence and One in the Presence and One in the Absence of CsA. *Cell* 66, 799 (1991).
	BV	Fuh et al. Rational design of potent antagonists to the human growth hormone receptor. *Science* 256, 1677-1680 (1992).
	BW	Galat et al. A Rapamycin-Selective 25 kDa Immunophilin. *Biochemistry* 31, 2427-2434 (1992).

COPY OF PAPERS ORIGINALLY FILED

Form PTO-1449 **INFORMATION DISCLOSURE CITATION IN AN APPLICATION** *(Use several sheets if necessary)*	Docket Number (Optional) APBI-P16-316	Application Number 09/466,568
	Applicant Belshaw et al.	
	Filing Date December 17, 1999	Group Art Unit 1636

	BX	Ghosh et al. N,N'-Disuccinimidyl Carbonate: A Useful Reagent for Alkoxycarbonylation of Amines. *Tetrahedron Letters* 33,2781-2784 (1992).
	BY	Gottschalk et al. The Carboxy Terminal 100 Amino Acid Portion of the Insulin Receptor is Important for Isulin Signaling to Pyruvate Dehydrogenase. *Biochem. Biophys. Res. Comm.* 189, 906-911 (1992).
	BZ	Haendler et al. Yeast cyclophilin: isolation and characterization of the protein, cDNA and gene. *EMBO J.* 6, 947 (1987).
	CA	Haendler et al. Yeast cyclophilin: isolation and characterization of the protein, cDNA and gene. *Gene* 83, 39 (1989).
	CB	Harding et al. A Receptor for the Immunosuppressant FK506 is a cis-trans Peptidyl-Prolyl Isomerase. *Nature* 341, 758 (1989).
	CC	Herbst et al. Substrate Phosphorylation Specificity of the Human c-kit Receptor Tyrosine Kinase. *J. Biol. Chem.* 266, 19908-19916 (1991).
	CD	Howard et al. The CD3ζCytoplasmic Domain Mediates CD2-Induced T Cell Activation. *J. Exp. Med.* 176, 139-145 (1992).
	CE	Hultsch et al. Immunophilin Ligands Demonstrate Common Features of Signal Transduction Leading to Exocytosis or Transcription. *PNAS* 88, 6229-6233 (1991).
	CF	Hultsch et al. Inhibition of IgE Receptor-Mediated Exocytosis from Rat Basophilic Leukemia Cells by FK506 is Reversed by Rapamycin: Evidence for Common Signaling Pathways in Mast Cells and T Lymphocytes. *FASEB J.* 5, A1008 [3705] (1991).
	CG	Hung & Schreiber. CDNA Cloning of a Human 25 kDa FK506 and Rapamycin Binding Protein. *Biochem. Biophys. Res. Comm.* 184, 733 (1992).
	CH	Ikeda et al. Structural Basis for Peptidomimicry by a Natural Product. *J. Am. Chem. Soc.* 116, 4143-4144 (1994).
	CI	Irving & Weiss. The Cytoplasmic Domain of the T Cell Receptor ς Chain is Sufficient to Couple to Receptor-Associated Signal Transduction Pathways. *Cell* 64, 891-901 (1991).
	CJ	Itoh & Nagata. A Novel Protein Domain Required for Apoptosis. *J. B. C.* 268, 10932 (1993).
	CK	Itoh et al. Effect of bcl-2 on Fas Antigen Mediated Cell Death. *J. Immunol.* 151, 621-627 (1993).
	CL	Jin et al. Molecular cloning of a membrane-associated human FK506- and rapamycin-binding protein, FKBP-13. *PNAS* 88, 6677 (1991).
	CM	Kao et al. Nuclear target of cyclosporin A and FK506 action is specifically bound by a heterodimeric protein comprising molecular weights 90K and 45K. *J. Cell. Biochem. Suppl.* 0 (16 Part B), 239, Abstract #H523 (1992).
	CN	Kaye et al. Effects of Cyclosporin A and FK506 on Fce Receptor type I-Initiated Increases in Cytokine mRNA in Mouse Bone Marrow-Derived Progenito Mast Cells: Resistance to FK506 is Associated with a Deficiency in FKBP12. *PNAS* 89, 8542-4546 (1992).

Form PTO-1449 **INFORMATION DISCLOSURE CITATION IN AN APPLICATION** *(Use several sheets if necessary)*	Docket Number (Optional) APBI-P16-316	Application Number 09/466,568
	Applicant Belshaw et al.	
	Filing Date December 17, 1999	Group Art Unit 1636

	CO	Ke et al. Crystal Structures of Cyclophilin A Complexed with Cyclosporin A and N-methyl-4-[(E)-2-Butenyl]-4,4-Dimthyltheonine Cyclosporin A. *Structure* 2, 33-44 (1994).
	CP	Kinet. Antibody-Cell Interactions: Fc Receptors. *Cell* 57, 351-354 (1989).
	CQ	Krishnamurthy. Lithium Tris[(3-ethyl-3-pentyl)oxy]aluminum Hydride. A New Remarkably Chemoselective Reagent for the Reduction of Aldehydes in the Presence of Ketones. *J. Org. Chem.* 46, 4628-4629 (1981).
	CR	Kruskal et al. Phagocytic Chimeric Receptors Require Both Transmembrane and Cytoplasmic Domains from the Mannos Receptor. *J. Exp. Med.* 176, 1673-1680 (1992).
	CS	Lammers et al. Differential Signaling Potential in Insulin- and IGF-1-receptor Cytoplasmic Domains. *EMBO J.* 8, 1369-1375 (1989).
	CT	Lane et al. Complete Amino Acid Sequence of the FK506 and Rapamycin Binding Protein, FKBP, Isolated from Calf Thymus. *J. Prot. Chem.* 10, 151-160 (1991).
	CU	Lanier et al. Co-association of CD3ς with a Receptor (CD16) for IgG Fc on Human Natural Killer Cells. *Nature* 342, 803-805 (1989).
	CV	Larson & Nuss. Cyclophilin-dependent stimulation of transcriptionby cyclosporin A. *PNAS* 90, 148 (1993).
	CW	Lee et al. Functional Dissection of Structural Domains in the Receptor for Colony Stimulating Factor-1. *J. Biol. Chem.* 267, 16472-16483 (1992).
	CX	Lee et al. HER2 Cytoplasmic Domain Generates Normal Mitogenic and Transforming Signals in a Chimeric Receptor. *EMBO J.* 8, 167-173 (1989).
	CY	Lehtola et al. A chimeric EGFR/neu receptor in functional analysis of theneu oncoprotein. *Acta Oncologia* 31, 147-150 (1992).
	CZ	Lehtola et al. Receptor Downregulation and DNA Synthesis are Modulated by EGF and TPA in Cells Expressing an EGF/neu Chimera. *Growth Factors* 1, 323-334 (1989). – ABSTRACT ONLY
	DA	Lehvaslaiho et al. A Chimeric EGF-R-neu Proto-Oncogene Allows EGF to Regulate neu Tyrosine Kinase and Cell Transformation. *EMBO J.* 8, 159-166 (1989).
	DB	Letourner & Klausner. Activation of T Cells by a Tyrosine Kinase Activation Domain in the Cytoplasmic Tail of CD3 ∈. *Science* 258, 123-126 (1992).
	DC	Lev et al. Receptor functions and ligand-dependent transforming potential of a chimeric kit proto-oncogene. *Mol. Cell. Biol.* 10, 6064-6068 (1990).
	DD	Lev et al. A Specific Combination of Substrates is Involved in Signal Transduction by the kit-Encoded Receptor. *EMBO J.* 10, 647-654 (1991).
	DE	Levaslaiho et al. Regulation by EGF is maintained in an overexpressed chimeric EDG/neu receptor tyrosine kinase. *Cell. Biochem.* 42, 123-133 (1990).

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	Docket Number (Optional) APBI-P16-316	Application Number 09/466,568
	Applicant Belshaw et al.	
	Filing Date December 17, 1999	Group Art Unit 1636

	DF	Liu. FK506 and cyclosporin, molecular probes for studying intracellular signal transduction. *Immunology Today* 14, 290 (1993).
	DG	Liu et al. Calcineurin is a Common Target of Cyclophilin-Cyclosporin A and FKBP-FK506 Complexes. *Cell* 66, 807 (1991).
	DH	Liu et al. Cloning, expression, and purification of human cyclophilin in Escherichia coli and assessment of the catalytic role of cysteines by site-directed mutagenesis. *PNAS* 87, 2304 (1990).
	DI	Liu et al. Inhibition of T Cell Signaling by Immunophilin-Ligand Complexes Correlates With Loss of Calcineurin Phosphatase Activity. *Biochemistry* 31, 3896-3901 (1992).
	DJ	Maki et al. Complementary DNA encoding the human T-cell FK506-binding protein, a peptidylprolyl cis-trans isomerase distinct from cyclophilin. *PNAS* 87, 5440 (1990).
	DK	Mares et al. A Chimera between Platelet-Derived Growth Factor B-receptor and Fibroblast Growth Factor Receptor-1 Stimulates Pancreatic β-DNA Synthesis in the Presence of PDGF-BB. *Growth Factors* 6, 93-101 (1992).
	DL	Margolis et al. All Autophosphorylation Sites of Epidermal Growth Factor (EGF) Receptor and HER2/neu are Located in their Carboxyl-Terminals Tails. *J. Biol. Chem.* 264, 10667-10671 (1989).
	DM	Mattila et al. The Actions of Cyclosporin A and FK506 Suggest A Novel Step in the Activation of T Lymphocytes. *EMBO J.* 9, 4425-4433 (1990).
	DN	Meyer et al. Synthetic Investigations of Rapamycin. 1. Synthesis of a C10-C21 Fragment. *J. Org. Chem.* 57, 5058-5060 (1992).
	DO	Michnick et al. Solution Structure of FKBP, a Rotamese Enzyme and Receptor for FK506 and Rapamycin. *Science* 252, 836-839 (1991).
	DP	Moe et al. Transmembrane Signaling by a Chimera of the Escherichia coli Aspartate Receptor and the Human Insulin Receptor. *PNAS* 86, 5683-5687 (1989).
	DQ	Nakatsuka et al. Total Syntheses of FK506 and an FKBP Probe Reagent, (C8, C9-13C2)-FK506. *J. Am. Chem. Soc.* 112, 5583 (1990).
	DR	Nussbaumer et al. C9-Imino and C10-Amino Derivatives of Ascomycin (21-Ethyl-FK506). *Tetrahedron Letters* 33, 3845-3846 (1992).
	DS	Orloff et al. Family of Disulphide-Linked Dimers Containing the ς and η Chains of the T-Cell Receptor and the y Chain of the Fc Receptors. *Nature* 347, 189-191 (1990).
	DT	Palmiter et al. Transgenic Mice. *Cell* 41, 343-345 (1985).
	DU	Patchett et al. Analogs of Cyclosporin A Modified at the D-ALA[8] Position. *J. Antibiotics* 45, 94-102 (1992).
	DV	Peles et al. Regulated Coupling of the Neu Receptor to Phosphatidylinositol. *J. Biol. Chem.* 267, 12266-12274 (1992).

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	Docket Number (Optional) APBI-P16-316	Application Number 09/466,568
	Applicant Belshaw et al.	
	Filing Date December 17, 1999	Group Art Unit 1636

	DW	Price et al. Tissue-specific cyclophilin B: A second cyclophilin gene encodes a peptidyl-prolyl isomerase with a signal sequence. *PNAS* 88, 1903 (1991).
	DX	Ptashne et al. Activators and Targets. *Nature* 346, 329-331 (1990).
	DY	Ragan et al. Studies of the Immunosuppressive Agent FK506: Synthesis of an Advanced Intermediate. *J. Org. Chem.* 54, 4267 (1989).
	DZ	Reins et al. Anti-epidermal growth factor receptor monoclonal antibodies affecting signal transduction. *J. Cell. Biol.* 51, 236-248 (1993).
	EA	Riedel et al. Cytoplasmic Domains Determine Signal Specificity, Cellular Routing Characteristics and Influence Ligand Binding of Epidermal Growth Factor and Insulin Receptors. *EMBO J.* 8, 2943-2954 (1989).
	EB	Romeo et al. Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. *Cell* 64, 1037-1046 (1991).
	EC	Romo et al. Synthetic Investigations of Rapamycin. 2. Synthesis of a C22-C42 Fragment. *J. Org. Chem.* 57, 5060-5063 (1992).
	ED	Romo et al. Total Synthesis of Rapamycin Using an Evans-Tischenko Fragment Coupling. *J. Am. Chem. Soc.* 115, 7906-7907 (1993).
	EE	Rosen, M. K. The molecular basis of receptor-ligand-receptor interactions: Studies of the immunophilin FKBP12, Abstract of Doctoral Thesis (1993).
	EF	Rosen et al. Activation of an Inactive Immunophilin by Mutagenesis. *J. Am. Chem. Soc.* 115, 821-822 (1993).
	EG	Rosen et al. Inhibition of FKBP Rotamase Activity by Immunosuppressant FK506: A Twisted Amide Surrogate. *Science* 248, 863 (1990).
	EH	Rosen et al. Natural Products as Probes of Cellular Function: Studies of Immunophilins. *Angew. Chemie. Int. Ed. Eng.* 31, 384-400 (1992).
	EI	Rosen et al. Proton and Nitrogen Sequential Assignments and Secondary Structure Determination of the Human FK506 and Rapamycin Binding Protein. *Biochemistry* 30, 4774-4789 (1991).
	EJ	Rosen et al. Study of Receptor-Ligand Interactions Through Receptor Labeling and Isotope-Edited NMR. *J. Org. Chem.* 56, 6262 (1991).
	EK	Roussel et al. Antibody-Induced Mitogenicity Mediated by a Chimeric CD2-c-fms Receptor. *Mol. Cell. Biol.* 10, 2407-2412 (1990).
	EL	Rudert et al. Apoptosis in L929 cells expressing a CD40/Fas chimeric receptor: Dissociation of stimulatory from inhibory death signaling functions. *Biochem. Biophys. Res. Comm.* 204, 1102 (1994).
	EM	Sampson & Gotschlich. Neisseria meningitidis encodes an FK506-inhibitable rotamase. *PNAS* 89, 1164 (1992).

Form PTO-1449 **INFORMATION DISCLOSURE CITATION IN AN APPLICATION** *(Use several sheets if necessary)*	Docket Number (Optional) APBI-P16-316	Application Number 09/466,568
	Applicant Belshaw et al.	
	Filing Date December 17, 1999	Group Art Unit 1636

	EN	Schreiber, S. L. Analysis of cyclosporin-receptor interaction: Synthesis of semi-peptide and non-peptide analogs of cyclosporin A. Abstract of NIH Grant P01GM406600001 (1989).
	EO	Schreiber, S. L. Chemistry and Biology of the Immunophilins and their Immunosuppressive Ligands. *Science* 251, 283 (1991).
	EP	Schreiber, S. L. Immunophilin-Sensitive Phosphatase Action in Cell Signaling Pathways. *Cell* 70, 365-369-8 (1992).
	EQ	Schreiber et al. Immunophilin-Ligand Complexes as Probes of Intracellular Signaling Pathways. *Transplantation Proceedings* 23, 2839 (1991).
	ER	Schreiber, S. L. Synthesis of materials with physiological properties. Abstract of NIH Grant R37GM38627, (1992).
	ES	Schreiber, S. L. Synthesis of materials with physiological properties. Abstract of NIH Grant R37GM38627, (1987).
	ET	Schreiber et al. Is There a Scaffolding Domain within the Structure of the Immunosuppressive Agent Cyclosporin A (CsA)? Studies of the Cyclophilin Binding Domain of CsA. *Tetrahedron Lett.* 29, 6577 (1988).
	EU	Schreiber et al. The Mechanism of Action of Cyclosporin A and FK506. *Immunology Today* 13, 136-142 (1992).
	EV	Schreiber et al. Molecular Recognition of Immunophilins and Immunophilin-Ligand Complexes. *Tetrahedron* 148, 2545-2558 (1992).
	EW	Schreiber et al. Studies Relating to the Synthesis of the Immunosuppressive Agent FK506: Application of the Two Directional Chain Synthesis Strategy to the Pyranose Moiety. *J. Org. Chem.* 54, 9, 15 (1989).
	EX	Schreiber et al. Studies Relating to the Synthesis of the Immunosuppressive Agent FK506: Coupling of Fragments via a Stereoselective Trisubstituted Olefin Forming Reaction Sequence. *J. Org. Chem.* 54, 17 (1989).
	EY	Schultz et al. Atomic Structure of the Immunophilin FKBP13-FK506 Complex: Insights Into the Composite Binding Surface for Calcineurin. *J. Am. Chem. Soc.* 116, 3129-3130 (1994).
	EZ	Seedorf et al. Analysis of platelet-derived growth factor receptor domain function using a novel chimeric receptor approach. *J. Biol. Chem.* 266, 12424-12431 (1991).
	FA	Seedorf et al. Differential effects of carboxy-terminal sequence deletions on platelet-derived growth factor receptor signaling activities and interactions with cellular substrates. *Mol. Cell. Biol.* 12, 4347-4356 (1992).
	FB	Selvakumaran et al. Myeloblastic leukemia cells conditionally blocked Myc-estrogen receptor chimeric transgenes for terminal differentiation coupled to growth arrest and apoptosis. *Blood* 81, 2257 (1993).
	FC	Serafini et al. Selection and characterization of mutants in a signal transduction/transmission pathway. *J. Cell. Biochem. Suppl.* 0 (6 Part A), 89, Abstract #B234 (1992).
	FD	Shaw et al. Identification of a Putative Regulator of Early T Cell Activation Genes. *Science* 241, 202 (1988).

COPY OF PAPERS ORIGINALLY FILED

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	Docket Number (Optional) APBI-P16-316	Application Number 09/466,568
	Applicant Belshaw et al.	
	Filing Date December 17, 1999	Group Art Unit 1636

	FE	Sisken et al. Activation of the neu Tyrosine Kinase. *J. Cell. Biol.* 109, 1911-1919 (1989).
	FF	Smith et al. FKBP54, a Novel FK506 Binding Protein in Avian Progesterone Receptor Complexes and HeLa Extracts. *J. Biol. Chem.* 268, 24270-24273 (1993).
	FG	Somers et al. Synthesis and Analysis of 506BD, a High Affinity Ligand to the Immunophilin, FKBP. *J. Am. Chem. Soc.* 113, 8045-8056 (1991).
	FH	Standaert, R. F. Biochemical and structural studies of the FK506- and rapamycin-binding proteins (FKBPs). *Abstract of Doctoral Thesis* (1992).
	FI	Standaert et al. Molecular cloning and overexpression of the human FK506-binding protein FKBP. *Nature* 346, 671 (1990).
	FJ	Tai et al. Association of a 59-Kilodalton Immunophilin with the Glucocorticoid Receptor Complex. *Science* 256, 1315-1318 (1992).
	FK	Tai et al. P59 (FK506 Binding Protein 59) Interaction with Heat Shock Proteins is Highly Conserved and May Involve Proteins Other Than Steroid Receptors. *Biochemistry* 32, 8842-8847 (1993).
	FL	Tanida et al. Yeast Cyclophilin-related gene encodes a nonessential second peptidyl-prolyl cis-trans isomerase with the secretory pathway. *Transplantation Proceedings* 23, 2856 (1991).
	FM	Traber et al. Cyclosporins – New Analogues by Precursor Directed Biosynthesis. *J. Antibiotics* 42, 591-597 (1989).
	FN	Ullman et al. Site of action of cyclosporin and FK506 in the pathways of communication between the T-lymphocyte antigen receptor and the early activation genes. *Transplant. Proceed.* 23, 2845 (1991).
	FO	Van Duyne et al. Atomic Structure of FKBP-FK506, an Immunophilin-Immunosuppressant Complex. *Science* 252, 839-842 (1991).
	FP	Van Duyne et al. Atomic Structure of the Rapamycin human immunophilin FKBP-12 complex. *J. Am. Chem. Soc.* 113, 7433 (1991).
	FQ	Van Duyne et al. Atomic Structures of the Human Immunophilin FKBP12 Complexes with FK506- and Rapamycin. *J. Mol. Biol.* 229, 105-124 (1993).
	FR	VanRheenen et al. An Improved Catalytic OsO4 Oxidation of the Olefins to Cis-1,2 Glycols Using Tertiary Amine Oxides as the Oxidant. *Tetrahedron Letters* 23, 1973-1976 (1976).
	FS	Venkitaraman et al. Interleukin 7 receptor functions by recruiting the tyrosine kinase $p59^{tym}$ through a segment of its cytoplasmic tail. *PNAS* 89, 12083-12087 (1992).
	FT	Verweij et al. Cell Type Specificity and Activation Requirements for NFAT-1 (Nuclear Factor of Activated T-Cells) Transcriptional Activity Determined by a New Method Using Transgenic Mice to Assay Transcriptional Activity of an Individual Nuclear Factor. *J. Biol. Chem.* 265, 15788 (1990).
	FU	Walsh et al. Cyclosporin A, the Cyclophilin Class of Peptidylprolyl Isomerases, and Blockade of T Cell Signal Transduction. *J. Biol. Chem.* 267, 13115 (1992).

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION *(Use several sheets if necessary)*	Docket Number (Optional) APBI-P16-316	Application Number 09/466,568
	Applicant Belshaw et al.	
	Filing Date December 17, 1999	Group Art Unit 1636

	FV	Wandless et al. FK506 and Rapamycin Binding to FKBP: Common Elements Involved in Immunophilin-Ligand Complexation. *J. Am. Chem. Soc.* 113, 2339-2341 (1991).
	FW	Wandless, T. J. Turing genes on and off using FKBP and FK506. *Doctoral Thesis* (1993).
	FX	Watanabe-Fukunga et al. Lymphoproliferation Disorder in Mice Explained by Defects in Fas Antigen that Mediates Apoptosis. *Nature* 356, 314-317 (1992).
	FY	Weissman et al. Molecular Cloning and Chromosomal Localization of the Human T-Cell Receptor ζ Chain: Distinction from the Molecular CD3 Complex. *PNAS* 85, 9709-9713 (1988).
	FZ	Wennstrom et al. The platelet-derived growth factor beta-receptor kinase insert confers specific signaling properties to a chimeric fibroblast growth factor receptor. *J. Biol. Chem.* 267, 13749-13756 (1992).
	GA	Wittbrodt et al. The Xmrk Receptor Tyrosine Kinase is Activated in Xiphophorous Maligant Melanoma. *EMBO J.* 11, 4239-4246 (1992).
	GB	Yang et al. A Composite FKBP12-FK506 Surface That Contacts Calcineurin. *J. Am. Chem. Soc.* 115, 819-820 (1993).
	GC	Yarden et al. Growth factor receptor tyrosine kinases. *Ann. Rev. Biochem.* 57, 443-478 (1988).
	GD	Zelle et al. Systematic Degradation of Zincophorin: A Stereoselective Synthesis of the C17-C25 Fragment. *J. Org. Chem.* 51, 5032-5036 (1986).
	GE	Zhang et al. The insulin receptor-related receptor. *J. Biol. Chem.* 267, 18320-18328 (1992).
	GF	Zydowsky et al. Active site mutants of human cyclophilin A separate peptidyl-prolyl isomerase activity from cyclosporin A binding and calcineurin inhibition. *Prot. Sci.* 1, 1092 (1992).
	GG	Zydowsky et al. Overexpressoin, purification, and characterization of yeast cyclophilins A and B. *Protein Sci.* 1, 961 (1992).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.